(BSEM) –
-
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference
-
BioStem Technologies, Inc. (BSEM) Reports revenue
-
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
-
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
-
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market
-
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
-
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role
-
BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors
-
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions
-
BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors
-
BioStem Technologies, Inc. (BSEM) Tops Q3 EPS by 21c
-
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results
-
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services
-
BioStem Technologies Closes Oversubscribed $2M Private Placement
-
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje(R) in Diabetic Foot Ulcers
-
NovaBay Pharma (NBY) Announces Commercial Launch of Avenova Allograft
-
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
-
NovaBay Pharma (NBY) Enters Agreement with BioStem Technologies (BSEM) to Commercialize Amniotic Tissue Allograft as Avenova Allograft
-
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
-
Form D BIOSTEM TECHNOLOGIES
-
BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
-
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
-
BioStem Technologies Enters Into a Share Exchange Agreement
-
BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing
-
Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions
-
BioStem Technologies Announces Up-Listing to the OTCQB Venture Market
-
BioStem Technologies Announces Partnership with Kill Cliff FC
-
BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results
-
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call
-
BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer
-
BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
-
BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts
-
BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe
-
BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results
-
BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd
-
BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022
-
BioStem Technologies Reports March 31, 2022 Record Quarterly Financial Results
-
BioStem Technologies Inc. Reports December 31, 2021 Year End Financial Results
-
BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®
-
BioStem Technologies Reports Record Breaking Second Quarter Sales
-
BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
-
BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.
-
Form D BIOSTEM TECHNOLOGIES
-
BioStem Technologies Announces Filing of 2021 First Quarter Financial Reports
-
BioStem Technologies, Inc., Announces the Addition of Three Key Scientific Advisory Board Members
-
BioStem Technologies, Inc. Announces Launch of National Sales Force Expansion
-
BioStem Technologies, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2020
-
BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™
-
BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit
-
BioStem Technologies, Announces Filing of 2020 Quarterly Reports
Back to BSEM Stock Lookup